Back to News
Market Impact: 0.4
Geron Discontinues Phase 3 IMpactMF Trial Of Imetelstat In Myelofibrosis; Data Analysis Planned
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Geron plans to discontinue its Phase 3 IMpactMF trial of imetelstat in patients with relapsed or refractory myelofibrosis, following a recommendation from the independent Data Monitoring Committee. The article provides no reason for the recommendation or additional clinical results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
GERN-0.85
More News
- Wedbush cuts Geron stock price target to $5 on study halt
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- SK Hynix says the memory-chip shortage will last until 2030—and more than half its production is booked for the next two years
- China’s tech darlings are losing their shine. Here’s what’s behind the sell-off
- GE Vernova shares slip despite a beat-and-raise. What the sellers are getting wrong